A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine if methadone treatment will affect the blood levels of zidovudine (AZT) in
patients with AIDS or AIDS-related complex (ARC) who are receiving oral AZT and methadone
therapy. In addition, the blood levels of methadone both before and during AZT treatment will
be studied, and patients receiving daily oral methadone treatment will be evaluated for signs
of narcotic withdrawal during treatment with AZT.
The number of deaths due to AIDS in high-risk populations continues to increase. Nationwide
approximately 25 percent of AIDS patients are intravenous (IV) drug abusers, and it is very
likely that an increasingly larger number of AIDS patients receiving AZT therapy will have
had a history of IV drug abuse. The major chemical treatment for IV drug abuse is daily
methadone maintenance therapy, and IV drug abusers who are HIV positive represent a large
number of patients who will undergo long-term treatment with both methadone and AZT.
Therefore, the study of potential drug interactions is essential.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)